Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03571633
Recruitment Status : Recruiting
First Posted : June 27, 2018
Last Update Posted : July 10, 2019
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Centre Leon Berard

Brief Summary:
First preclinical data suggest that pegfilgrastim could constitute a potent adjuvant for immunotherapy with mAb possessing ADCC/ADCP properties as trastuzumab. Combined treatment of pegfilgrastim and trastuzumab should translate into an increased rate of pathological clinical response. Therefore the investigators' proposal is to evaluate the clinical and biological impact of pegfilgrastim in combination with trastuzumab + paclitaxel in HER2-positive early stage breast cancer patients. Breastimmune02 is a multicenter, randomized, open-label, Phase II trial. Operable HER2+ breast cancer patients previously treated with 4 cycles of standard adriamycine/cyclophosphamide (AC) chemotherapy will be randomized (1:1) to receive in the neoadjuvant setting:Arm A: weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) + pegfilgrastim (Q3W) versus Arm B: weekly paclitaxel + trastuzumab (Q3W).Stratification criteria will be: cN0 versus cN1.

Condition or disease Intervention/treatment Phase
HER2-positive Breast Cancer Operable Breast Cancer Drug: Trastuzumab + Paclitaxel Drug: Pegfilgrastim Phase 2

Detailed Description:

The duration of the neoadjuvant treatment period is planned to be 12 weeks (4 cycles of 3 weeks), except in case of Inacceptable toxicity, or Patient decision, or Withdrawal of consent, or Clinical/radiological signs of disease progression.This neoadjuvant treatment period will be ended with a short term safety visit (STSVNeo) to be scheduled 28 days after the last dose of study treatments (considering the latest study treatments administered). Following the STSVNeo, patients will undergo surgery as per usual practice and pathological response will be centrally assessed by a referent pathologist blinded for the treatment arms.Following surgery, all patients will be treated in the adjuvant setting with trastuzumab administered every 3 weeks for up to 12 months in both arms with clinical assessments every 3 months (cf. Réseau régional de Cancérologie, http://espacecancer.sante-ra.fr/Pages/Accueil.aspx). In case of RH+ disease, endocrine therapy may be initiated as per standard treatment guidelines.This adjuvant treatment period is planned for a maximum of 12 months; except in case of Inacceptable toxicity, or Patient decision, or Withdrawal of consent, or Clinical/radiological signs of disease progression. All randomized and treated patients will be followed-up for relapse and survival for at least 15 months post-randomization (i.e. 1 year post-surgery).

A total of 90 patients will be randomized in the study. (45 per arm). All the data concerning the patients will be recorded in the electronic case report form (eCRF) throughout the study serious adverse event (SAE) reporting will be also paper-based by e-mail and/or Fax. The sponsor will perform the study monitoring and will help the investigators to conduct the study in compliance with the clinical trial protocol, Good Clinical Practices (GCP) and local law requirements


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients
Actual Study Start Date : August 6, 2018
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Paclitaxel+Trastuzumab+Pegfilgrastim

NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).

ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)

Drug: Trastuzumab + Paclitaxel
During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)

Drug: Pegfilgrastim
During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
Other Name: Neulasta

Active Comparator: Paclitaxel+Trastuzumab

NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).

ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)

Drug: Trastuzumab + Paclitaxel
During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)




Primary Outcome Measures :
  1. Pathological complete response rate (pCR) [ Time Frame: 16 weeks after start of treatment ]
    Defined as ypT0 ypN0 or ypT0/is ypN0 after 12 weeks of treatment by trastuzumab + paclitaxel ± pegfilgrastim with ypT0/Tis ypN0 defined as absence of invasive cancer in the breast and axillary nodes in all surgically excised specimens.


Secondary Outcome Measures :
  1. Disease Free survival [ Time Frame: At least 15 months following randomisation ]
    From the date of randomisation until the date of event defined as the first documented relapse after surgery or death from any cause.

  2. Time to relapse [ Time Frame: At least 15 months following randomisation ]
    From the time of treatment start until the first documented relapse

  3. Overall survival [ Time Frame: At least 15 months following randomisation ]
    From the date of randomisation to the date of death from any cause

  4. Adverse events reporting [ Time Frame: At least 15 months following randomisation ]
    Based mainly on the frequency of AE graded according to the common toxicity criteria grading system (CTCAE-V4.03).


Other Outcome Measures:
  1. Trastuzumab ADCC activity [ Time Frame: At Baseline, at Day 1 of Cycle 2 (each cycle is a 21-day cycle) and at surgery ]
    Analysis of the levels of the ADCC tumor samples

  2. HER2 signaling [ Time Frame: At Baseline, at Day 1 of Cycle 2 (each cycle is a 21-day cycle) and at surgery ]
    Evaluation of the levels of phosphorylated components of PI3K/mTOR and Ras/Raf /MAPK signaling (IHC or IF)

  3. Immune effector cells activity [ Time Frame: At Baseline, at Day 1 of Cycle 2 (each cycle is a 21-day cycle) and at surgery ]
    Analysis of activity of immune effector cells (frequency, function, activation status and ADCC)

  4. TGFbeta levels [ Time Frame: At Baseline ]
    Levels of TGFβ (bioactive and non-bioactive) in serum, plasma and platelets



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patients aged ≥ 18 years at time of inform consent signature.
  • Histologically proven HER2 positive breast cancer defined as 3+ staining intensity by immunohistochemistry (IHC) or a 2+ IHC staining intensity and HER2 gene amplification by FISH.Note: HER2 status will be determined as per institutional practice.
  • Operable breast tumor with tumor size and staging: > 20 mm, cN0 or cN1, M0.
  • No radiological sign of disease progression at time of randomisation.
  • Patient previously treated by 4 cycles of AC or 3 to 4 cycles of FEC without febrile neutropenia and without prior pegfilgrastim treatment.
  • Availability of a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen from initial diagnosis (i.e. an archival paraffin block is preferred; or at least 20 unstained slides) with its histological report.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Adequate organ function as defined by the following lab tests (to be carried out within 7 days prior C1D1):Bone marrow (Absolute neutrophil count ≥ 1.5 x 109/L, Platelet count > 100 x 109/L, (without transfusion within 21 days prior to C1D1), Hemoglobin value ≥ 9 g/dL), Renal function (Calculated creatinine clearance by MDRD or CKD-EPI >50 mL/min/1.73m2 or serum creatinine < 1.5ULN), Liver function (Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3ULN, Total serum bilirubin ≤ 1.5 ULN (except for patients with Gilbert disease for whom a total serum bilirubin ≤3 ULN is acceptable), Coagulation (INR and aPTT≤ 1.5 ULN)
  • Adequate cardiac function with Mean resting corrected QT interval (QTc), calculated using Fridericia's formula, ≤470ms obtained from 3 electrocardiograms (ECGs) and Systolic blood pressure <160mmHg and Diastolic blood pressure <100mmHg (hypertension controlled by standard medical treatment is allowed)
  • Women of childbearing potential (entering the study after a confirmed menstrual period and who have a negative pregnancy test within 7 days before C1D1) must agree to use two methods of medically acceptable forms of contraception from the date of negative pregnancy test to 3 months after the last study drug intake
  • Patients should be able and willing to comply with study visits and procedures as per protocol
  • Patients should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed.
  • Patients must be covered by a medical insurance.

Exclusion Criteria:

  • Patients with inflammatory breast cancer.
  • Previous exposure to pegfilgrastim or trastuzumab. Note: the use of filgrastim (non pegylated form only) is authorized prior to the randomisation.
  • Patients requiring the concomitant use of any forbidden treatment including: Any other anti-cancer treatments not listed in the protocol, including chemotherapy, radiotherapy, immunotherapy, targeted therapy or biologic therapy for cancer treatment, Any investigational treatment.
  • Any contra-indication to trastuzumab, paclitaxel, and pegfilgrastim respective SPCs including:Hypersensitivity to trastuzumab, murine proteins, or to any of the excipients listed in trastuzumab SPC, Severe dyspnea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy, Hypersensitivity to pegfilgrastim or filgrastim, or to any of the excipients listed in SPC, Hereditary problems of fructose intolerance, Hypersensitivity to paclitaxel or to any excipient, particularly macrogolglycerol ricinoleate, Patients with history of or active cardiac disease including myocardial infarction (MI), angina pectoris requiring medical treatment, congestive heart failure NYHA (New York Heart Association) Class ≥II, other cardiomyopathy, cardiac arrhythmia requiring medical treatment, clinically significant cardiac valvular disease, and hemodynamic effective pericardial effusion.
  • Active secondary malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints and is approved by the sponsor. Examples of the latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix. Patients with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.
  • Pregnant or breast-feeding female patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03571633


Contacts
Layout table for location contacts
Contact: Olivier TREDAN, MD 04 78 78 28 28 olivier.tredan@lyon.unicancer.fr

Locations
Layout table for location information
France
Centre Leon Berard Recruiting
Lyon, France
Contact: Olivier TREDAN         
Principal Investigator: Olivier TREDAN         
Sub-Investigator: Thomas BACHELOT         
Sub-Investigator: Olivia BALLY         
Sub-Investigator: Alice BONNEVILLE-LEVARD         
Sub-Investigator: Mehdi BRAHMI         
Sub-Investigator: Olfa DERBEL MILED         
Sub-Investigator: Armelle DUFRESNE         
Sub-Investigator: Pierre-Etienne HEUDEL         
Sub-Investigator: Isabelle RAY-COQUARD         
Sub-Investigator: Pauline ROCHEFORT         
Sub-Investigator: Philippe TOUSSAINT         
HCL - Centre Hospitalier Lyon Sud Active, not recruiting
Lyon, France
Hopital Prive Jean Mermoz Recruiting
Lyon, France
Contact: Olfa Derbel Miled         
Principal Investigator: Olfa Derbel Miled, MD         
Sub-Investigator: Olivia Bally, MD         
Sub-Investigator: Dominique Beal-ardisson, MD         
Institut de Cancerologie Lucien Neuwirth Recruiting
Saint-Priest-en-Jarez, France
Contact: Jean-Philippe Jacquin         
Principal Investigator: Jean-Philippe Jacquin, MD         
Sub-Investigator: Olivier Collard, MD         
Sub-Investigator: Benoîte Mery, MD         
Clinique Charcot Recruiting
Sainte-Foy-lès-Lyon, France
Contact: Nicolas Carrabin         
Principal Investigator: Nicolas Carrabin, MD         
Sub-Investigator: Ouarda Kenouchi, MD         
Sub-Investigator: Yann Molin, MD         
Sponsors and Collaborators
Centre Leon Berard
Amgen
Investigators
Layout table for investigator information
Principal Investigator: Olivier TREDAN, MD Centre Leon Berard

Publications:

Layout table for additonal information
Responsible Party: Centre Leon Berard
ClinicalTrials.gov Identifier: NCT03571633     History of Changes
Other Study ID Numbers: ET17-057
2017-002069-22 ( EudraCT Number )
First Posted: June 27, 2018    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Centre Leon Berard:
Pegfilgrastim
Trastuzumab/Paclitaxel
Antibody-dependent cell-mediated cytotoxicity

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Albumin-Bound Paclitaxel
Trastuzumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological